MBLX Metabolix Inc

Yield10 Bioscience to Announce Third Quarter 2022 Financial Results and Host a Conference Call on Monday, November 14, 2022

Yield10 Bioscience to Announce Third Quarter 2022 Financial Results and Host a Conference Call on Monday, November 14, 2022

WOBURN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2022 financial results and provide a corporate update on Monday, November 14, 2022.

Management will host a conference call on Monday, November 14, 2022 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, there will be a question and answer session.

To listen to the conference call, interested parties within the U.S. should call 1-800-715-9871. International callers should call . Reference Event ID: 2201826. The call will also be available through a live webcast and will reference a slide deck, both of which may be accessed through the investor relations section of the Company’s website at .

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait Factory”, to develop improved Camelina varieties to produce proprietary seed products, and to discover high value genetic traits for the agriculture and food industries. Our goals are to efficiently establish a high value seed products business based on developing superior varieties of Camelina to produce feedstock oils, nutritional oils, and PHA bioplastics, and to license our yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visit , or follow the Company on , and .

(YTEN-E)

Contacts:

Yield10 Bioscience:

Lynne H. Brum, (617) 682-4693,  

Investor Relations:

Bret Shapiro, (561) 479-8566,

Managing Director, CORE IR

Media Inquiries:

Eric Fischgrund,

FischTank PR



EN
07/11/2022

Underlying

MBLXMetabolix Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Metabolix Inc

 PRESS RELEASE
Free
MBLX METABOLIX INC

Yield10 Bioscience Announces Second Quarter 2024 Financial Results

Yield10 Bioscience Announces Second Quarter 2024 Financial Results WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July,” said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. “We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our sh...

August 14, 2024 1 EN
 PRESS RELEASE
Free
MBLX METABOLIX INC

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Asset...

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10’s assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding (“MOU”...

July 17, 2024 1 EN
 PRESS RELEASE
Free
MBLX METABOLIX INC

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Com...

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited (“Rothamsted”) has granted to the Company an exclusive global, commerc...

June 17, 2024 1 EN
 PRESS RELEASE
Free
MBLX METABOLIX INC

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbic...

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - EPA approved an amendment to the label of INTERLINE herbicideto include Camelina -The supplemental label now allows application of INTERLINE for over-the-top weed control in Camelina WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that UPL Ltd. (“UPL”) has received U.S. Environmental Protection Agency (“EPA”) approval to of INTERLINE® Herbicide to include the oilseed Camelina sativa (“Came...

May 23, 2024 1 EN
 PRESS RELEASE
Free
MBLX METABOLIX INC

Yield10 Bioscience Announces First Quarter 2024 Financial Results

Yield10 Bioscience Announces First Quarter 2024 Financial Results -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acids," said Oliver Peoples, ...

May 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch